The implementation of pharmacogenomic (PGx) testing in psychiatry remains modest, in part
due to divergent perceptions of the quality and completeness of the evidence base and …

Pharmacogenomics (PGx) is the study of genetic influences on an individual's response to
medications. Improvements in the quality and quantity of PGx research over the past two …

Current prescribing practices for major depressive disorder (MDD) produce limited treatment
success. Although pharmacogenomics may improve outcomes by identifying genetically …

Aim: To conducted a systematic review and meta-analysis of prospective, randomized
controlled trials (RCTs) that examined pharmacogenetic-guided decision support tools …

Precision medicine is increasingly recognized as a promising approach to improve disease
treatment, taking into consideration the individual clinical and biological characteristics …

Background Pharmacogenomic testing guided treatment have been developed to guide
drug selection or conversion in major depressive disorder patients. Whether patients benefit …

Nowadays, many relevant drug–gene associations have been discovered, but
pharmacogenomics (PGx)-guided treatment needs to be cost-effective as well as clinically …

The degree of agreement between four commercial pharmacogenetic-based decision
support tools (DSTs) was examined in five outpatients with major depressive disorder and at …

The promise of personalized genomic medicine is that knowledge of a person's gene
sequences and activity will facilitate more appropriate medical interventions, particularly …

The availability of clinical decision support systems (CDSS) and other methods for
personalizing medicine now allows evaluation of their real-world impact on healthcare …